ALK (ALKB/ OMX: ALK B / AKABY / AKBLF), a Denmark based provider of allergy prevention, diagnosis and treatment, announced on Monday that it has received U.S. FDA approval for its new line of AccuTest Allergy Skin Testing Devices, designed to enhance the accuracy and reliability of allergy testing and diagnosis.
This product line includes single-prick and multi-head devices, AccuTest-1, AccuTest-8 and AccuTest-10, as well as allergen well trays, aimed at improving diagnostic precision and patient comfort.
The multi-head applicators, available in 8-head and 10-head configurations, offer ergonomic designs with ribbed grips and larger top surface areas for more uniform pressure application, contributing to consistent results. The single-prick device, AccuTest-1, and the multi-head models feature smaller tines to improve accuracy and minimize discomfort.
AccuTest allergen well trays, compatible with the devices, feature a non-slip base and air-tight locking mechanism to prevent contamination, ensuring stability and accuracy during testing.
A recent study highlighted the AccuTest line's precision and its potential to reduce device variability, which could improve the reliability of allergy test results.
European Commission approves Palforzia for toddlers with peanut allergy
Eli Lilly and Co receives approval from FDA for Zepbound
CSL gains EMA backing for Garadacimab as HAE prophylactic treatment
Merck initiates Phase 3 trial for LAGEVRIO (molnupiravir)
Allergy Therapeutics reports positive data from VLP Peanut PROTECT trial
CBC Group acquires UCB's mature neurology and allergy business in China
Allergy Therapeutics begins Phase III trial for grass allergy treatment in children
IgGenix doses first patient in IGNX001 ACCELERATE Peanut Phase 1 trial